The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL)

Journal of Pathology

Volumn 224, Issue 3, 2011, Pages 355-366

  Bavi, Prashant ^a   Uddin, Shahab ^a   Bu, Rong ^a   Ahmed, Maqbool ^a   Abubaker, Jehad ^a   Balde, Valorie ^a   Qadri, Zeeshan ^a   Ajarim, Dahish ^b   Al Dayel, Fouad ^a   Hussain, Azhar R ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b King Faisal Heart Institute   (Saudi Arabia)

Author keywords

activated B cell (ABC) phenotype; apoptosis; DLBCL; NF B; NHL therapy; tissue microarray; XIAP

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; CASPASE; GENE PRODUCT; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CELL VIABILITY; CLINICAL FEATURE; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CASPASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME ACTIVATION; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NF-KAPPA B; NITRILES; PROGNOSIS; SULFONES; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79958191515     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2864     Document Type: Article

References (56)

1. Abramson JS, Shipp MA,. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106: 1164-1174. (Pubitemid 41129574)
2. Bazarbashi S,. Cancer Incidence Report Saudi Arabia 2004-2008. Ministry Of Health, Saudi Cancer Registry, Riyadh.
3. Staudt LM, Dave S,. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005; 87: 163-208. (Pubitemid 41135900)
4. Alizadeh AA, Eisen MB, Davis RE, et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511. (Pubitemid 30082188)
5. Shaffer AL, Rosenwald A, Staudt LM,. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002; 2: 920-932. (Pubitemid 37323213)
6. Rosenwald A, Wright G, Chan WC, et al., The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947. (Pubitemid 34651353)
7. Wright G, Tan B, Rosenwald A, et al., A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991-9996. (Pubitemid 37087056)
8. Davis RE, Brown KD, Siebenlist U, et al., Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861-1874. (Pubitemid 34028664)
9. Feuerhake F, Kutok JL, Monti S, et al., NF-κB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106: 1392-1399. (Pubitemid 41129606)
10. Lam LT, Davis RE, Pierce J, et al., Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11: 28-40. (Pubitemid 40075775)
11. Hayden MS, Ghosh S,. Signaling to NF-κB. Genes Dev 2004; 18: 2195-2224.
12. Baldwin AS,. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001; 107: 241-246. (Pubitemid 32157954)
13. Karin M, Ben-Neriah Y,. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000; 18: 621-663. (Pubitemid 30365393)
14. Luo JL, Kamata H, Karin M,. IKK/NF-κB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-2632. (Pubitemid 41434385)
15. Karin M, Lin A,. NF-κB at the crossroads of life and death. Nat Immunol 2002; 3: 221-227.
16. Siebenlist U, Brown K, Claudio E,. Control of lymphocyte development by nuclear factor-κB. Nat Rev Immunol 2005; 5: 435-445. (Pubitemid 40835032)
17. Compagno M, Lim WK, Grunn A, et al., Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-721.
18. Scheidereit C,. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene 2006; 25: 6685-6705. (Pubitemid 44657846)
19. Kim HJ, Hawke N, Baldwin AS,. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ 2006; 13: 738-747.
20. Karin M,. NF-κB and cancer: mechanisms and targets. Mol Carcinog 2006; 45: 355-361.
21. Jaffe ES, HN, Stein, H, Vardiman, JW,. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001.
22. Bavi P, Jehan Z, Atizado V, et al., Prevalence of fragile histidine triad expression in tumors from Saudi Arabia: a tissue microarray analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1708-1718. (Pubitemid 44497108)
23. Bavi P, Abubaker J, Hussain A, et al., Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Hum Pathol 2008; 39: 885-894.
24. Montagut C, Tusquets I, Ferrer B, et al., Activation of nuclear factor-κB is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006; 13: 607-616. (Pubitemid 43886680)
25. Charalambous MP, Lightfoot T, Speirs V, et al., Expression of COX-2, NF-κB-p65, NF-κB-p50 and IKKα in malignant and adjacent normal human colorectal tissue. Br J Cancer 2009; 101: 106-115.
26. Hussain AR, Uddin S, Ahmed M, et al., Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. J Pathol 2010.
27. Legrand-Poels S, Schoonbroodt S, Piette J,. Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem J 2000; 349: 765-773. (Pubitemid 30609407)
28. Abubaker J, Bavi P, Al-Haqawi W, et al., Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009; 219: 435-445.
29. Camp RL, Dolled-Filhart M, Rimm DL,. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10: 7252-7259. (Pubitemid 39487712)
30. Hans CP, Weisenburger DD, Greiner TC, et al., Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282. (Pubitemid 38029949)
31. Hoeller S, Tzankov A, Pileri SA, et al., Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 2010; 41: 352-357.
32. Oyama T, Yamamoto K, Asano N, et al., Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 2007; 13: 5124-5132. (Pubitemid 47502080)
33. Uddin S, Hussain AR, Siraj AK, et al., Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006; 108: 4178-4186. (Pubitemid 44913290)
34. Uddin S, Hussain AR, Manogaran PS, et al., Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 2005; 24: 7022-7030. (Pubitemid 41573631)
35. Hussain AR, Ahmed M, Al-Jomah NA, et al., Curcumin suppresses constitutive activation of nuclear factor-κB and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008; 7: 3318-3329.
36. Uddin S, Hussain A, Al-Hussein K, et al., Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem Biophys Res Commun 2004; 320: 932-938. (Pubitemid 38887233)
37. Hussain AR, Al-Jomah NA, Siraj AK, et al., Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res 2007; 67: 3888-3897. (Pubitemid 46762177)
38. Staudt LM, Singh H, Sen R, et al., A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. Nature 1986; 323: 640-643. (Pubitemid 16008559)
39. Al Kuraya K, Siraj AK, Bavi P, et al., High-throughput tissue microarray analysis of FHIT expression in diffuse large cell B-cell lymphoma from Saudi Arabia. Mod Pathol 2006; 19: 1124-1129. (Pubitemid 44106728)
40. Chen ZJ, Parent L, Maniatis T,. Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell 1996; 84: 853-862. (Pubitemid 26106855)
41. Bharti AC, Donato N, Singh S, et al., Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101: 1053-1062. (Pubitemid 36139379)
42. Hussain AR, Al-Rasheed M, Manogaran PS, et al., Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. Apoptosis 2006; 11: 245-254. (Pubitemid 43291024)
43. Jost PJ, Ruland J,. Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007; 109: 2700-2707. (Pubitemid 46482061)
44. Espinosa I, Briones J, Bordes R, et al., Activation of the NF-κB signalling pathway in diffuse large B-cell lymphoma: clinical implications. Histopathology 2008; 53: 441-449.
45. Baldwin AS, Jr,. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683. (Pubitemid 26130197)
46. + cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103: 3175-3184. (Pubitemid 38451696)
47. Biswas DK, Shi Q, Baily S, et al., NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 2004; 101: 10137-10142. (Pubitemid 38891208)
48. Bueso-Ramos CE, Rocha FC, Shishodia S, et al., Expression of constitutively active nuclearκ-B RelA transcription factor in blasts of acute myeloid leukemia. Hum Pathol 2004; 35: 246-253. (Pubitemid 38240909)
49. Ghosh S, Karin M,. Missing pieces in the NF-κB puzzle. Cell 2002; 109:(suppl): S81-96.
50. Schmid JA, Birbach A, Hofer-Warbinek R, et al., Dynamics of NF-κB and IκBα studied with green fluorescent protein (GFP) fusion proteins. Investigation of GFP-p65 binding to DNa by fluorescence resonance energy transfer. J Biol Chem 2000; 275: 17035-17042. (Pubitemid 30398945)
51. Gastman BR,. Apoptosis and its clinical impact. Head Neck 2001; 23: 409-425.
52. Nunez G, Benedict MA, Hu Y, et al., Caspases: the proteases of the apoptotic pathway. Oncogene 1998; 17: 3237-3245. (Pubitemid 29043976)
53. Duriez PJ, Desnoyers S, Hoflack JC, et al., Characterization of anti-peptide antibodies directed towards the automodification domain and apoptotic fragment of poly(ADP-ribose) polymerase. Biochim Biophys Acta 1997; 1334: 65-72. (Pubitemid 27063949)
54. Lenz G, Davis RE, Ngo VN, et al., Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676-1679. (Pubitemid 351432507)
55. Honma K, Tsuzuki S, Nakagawa M, et al., TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009; 114: 2467-2475.
56. Kato M, Sanada M, Kato I, et al., Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459: 712-716.